--- title: "BGM Group (BGM) news: offering" url: "https://aibio.space/companies/bgm/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BGM offering news: BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants. BGM Group Ltd. (NASDAQ: BGM), China." --- BGM BGM Group Ltd. NASDAQ · China # BGM Group (BGM) news BGM offering news Listings · 2026-09-24 ## [BGM Group announces 30-for-1 share consolidation, trading from October 1, 2026](https://aibio.space/news/bgm-group-announces-30-1-share-consolidation-trading-october-1-2026/) Class A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000. ## Latest BGM Group news 1. 2026-07-28 Listings [BGM Group regains Nasdaq compliance after filing its late 20-F](https://aibio.space/news/bgm-group-regains-nasdaq-compliance-after-filing-late-20/) BGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million. 2. 2026-06-09 Financings [BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants](https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/) BGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026. 3. 2026-01-30 Distress [BGM Group files late notice for 20-F over XY Management acquisition accounting](https://aibio.space/news/bgm-group-files-late-notice-20-f-xy-management-acquisition-accounting/) BGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited. ## BGM Group at a glance - **Ticker**: BGM - **Listing**: NASDAQ - **Country**: China - **Cash, Sep 30, 2025**: $9.8 million ### Related companies - [Tonghua Dongbao Pharmaceutical Co.](https://aibio.space/companies/tonghua-dongbao-pharmaceutical/) SSE: 600867 - [China National Accord Medicines Corporation](https://aibio.space/companies/china-national-accord-medicines/) SZSE: 000028 - [Wuhan YZY Biopharma Co.](https://aibio.space/companies/wuhan-yzy-biopharma/) HKEX: 2496 - [Shanghai InnoStar Bio-tech Co.](https://aibio.space/companies/shanghai-innostar-bio-tech/) SSE: 688710 - [Beijing Aosaikang Pharmaceutical Co.](https://aibio.space/companies/beijing-aosaikang-pharmaceutical/) SZSE: 002755 - [Shaanxi Kanghui Pharmaceutical Co.](https://aibio.space/companies/shaanxi-kanghui-pharmaceutical/) SSE: 603139 - [Nanjing King-friend Biochemical Pharmaceutical Co.](https://aibio.space/companies/nanjing-king-friend-biochemical-pharmaceutical/) SSE: 603707 - [Humanwell Healthcare (Group) Co.,Ltd.](https://aibio.space/companies/humanwell-healthcare/) SSE: 600079 ### Also on NASDAQ - [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) MIST - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) XERS - [Verastem](https://aibio.space/companies/verastem/) VSTM - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) OGI - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) SPRB - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA ## What BGM Group does BGM Group Ltd., formerly Qilian International Holding Group Limited, is a Cayman Islands company. Its PRC business is conducted through a variable interest entity, Gansu Qilianshan Pharmaceutical Co. Ltd. (Gansu QLS), under contractual arrangements. The filing defines the products the group works with. These include Ahan Antibacterial Paste, a disinfection paste made from a mixture of 11 traditional Chinese herbal ingredients used to treat refractory chronic skin diseases, and Gan Di Xin, an innovative antitussive and expectorant medicine made from raw licorice materials. Other defined products include Qilian Shan licorice extract, Qilian Shan oxytetracycline APIs, and a heparin sodium preparation, which is a primary ingredient for pharmaceutical companies producing medications for cardiovascular diseases, cerebrovascular diseases and hemodialysis. The filing also defines Xiongguan Organic Fertilizer and Zhu Xiaochang Sausage Casings, an all-natural food product. Its subsidiaries include Chengdu Qilianshan Biotechnology Co., Ltd., which is 79.71% owned by Gansu QLS, and Moshangfa (Gansu) Fertilizer Industry Co., Ltd. | Product or program | What it is | Stage | |---|---|---| | Ahan Antibacterial Paste | Disinfection paste from 11 traditional Chinese herbal ingredients for chronic skin diseases | | | Gan Di Xin | Antitussive and expectorant medicine made from raw licorice materials | | | Heparin Sodium Preparation | Primary ingredient for medications for cardiovascular and cerebrovascular diseases and hemodialysis | | | Qilian Shan Licorice Extract | Primary ingredient for manufacturing traditional licorice tablets | | | Qilian Shan Oxytetracycline APIs | Active ingredient for medications using oxytetracycline | | | Xiongguan Organic Fertilizer | Fertilizer product designed to improve crop yield | | Summarised from the company's [20-F filed Jul 21, 2026](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/bgm-20250930x20f.htm). ## BGM Group annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Revenue | [$37.9 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | [$25.1 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | | Research and development | [$672,669](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | | Net income (loss) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | | Cash from operations | [-$2.4 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | [$544,238](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | | Cash and equivalents | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) | Latest balance sheet, Sep 30, 2025 (20-F): cash and equivalents $9.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BGM Group Has BGM Group raised money recently? Our latest story on this, dated Jun 9, 2026: "BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/). What is the ticker symbol of BGM Group? BGM Group Ltd. trades under the ticker BGM on NASDAQ. Where is BGM Group listed? BGM Group Ltd. is listed on NASDAQ. What is the SEC CIK of BGM Group? The SEC Central Index Key (CIK) for BGM Group Ltd. is 1779578. Its filings are on SEC EDGAR. How many shares does BGM Group have outstanding? 35,750,000 shares as of 2023-09-30, per the cover page of its 20-F filed 2024-02-15. Which country or territory is BGM Group listed under? Our directory records BGM Group Ltd. under China. What does BGM Group do? Our directory classifies BGM Group Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of BGM Group? The ISIN recorded for BGM Group Ltd. is KYG7307E1310. Does aibio.space cover BGM Group? aibio.space lists BGM Group Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BGM Group incorporated? SEC records list its state or country of incorporation as E9. What does BGM Group develop? BGM Group Ltd., formerly Qilian International Holding Group Limited, is a Cayman Islands company. Its PRC business is conducted through a variable interest entity, Gansu Qilianshan Pharmaceutical Co. Ltd. (Gansu QLS), under contractual arrangements. What is Ahan Antibacterial Paste from BGM Group? Ahan Antibacterial Paste: Disinfection paste from 11 traditional Chinese herbal ingredients for chronic skin diseases What is Gan Di Xin from BGM Group? Gan Di Xin: Antitussive and expectorant medicine made from raw licorice materials What was BGM Group's revenue last year? $37.9 million for the fiscal year ended Sep 30, 2025, as reported to the SEC. Is BGM Group profitable? BGM Group Ltd. reported a net loss of $19.9 million for the fiscal year ended Sep 30, 2025, and used $2.4 million of cash in operations, per its annual report to the SEC. ## Investor discussion: BGM Group Members talk about BGM Group (BGM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BGM Group, newest first. Each line links the filing it comes from. 1. 2026-09-24 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926110425/tm2626068d1_6k.htm) 2. 2026-08-28 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926102847/tm2624176d1_ex99-1.htm) 3. 2026-08-11 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926094060/tm2622672d1_ex99-1.htm) 4. 2026-07-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926087324/tm2621474d1_6k.htm) 5. 2026-07-13 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926083125/tm2620216d1_6k.htm) 6. 2026-06-17 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926075173/tm2618062d1_ex99-1.htm) 7. 2026-06-09 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926071604/tm2617275d1_6k.htm) 8. 2026-05-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926063039/tm2614626d1_6k.htm) 9. 2026-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926057159/tm2613923d1_6k.htm) 10. 2026-04-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926052950/tm2613063d1_6k.htm) 11. 2026-01-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465926008672/tm264562d1_nt20f.htm) 12. 2025-02-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1779578/000110465925018576/tm257799d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BGM on TradingView](https://www.tradingview.com/symbols/NASDAQ-BGM/). ## SEC filings and registration - **SEC name**: BGM Group Ltd. - **CIK**: 1779578 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BGM (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: September 30 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: NO. 152 HONGLIANG EAST 1ST STREET, CHENGDU, 0000 - **Phone**: 86-028-64775180 - **Shares outstanding**: 35,750,000 as of 2023-09-30 (20-F filed 2024-02-15) - **Former names**: Qilian International Holding Group; Qilian International Holding Group Ltd ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926110425/tm2626068d1_6k.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926105911/tm2624933d1_6k.htm) filed 2026-09-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926102847/tm2624176d1_6k.htm) filed 2026-08-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926094060/tm2622672d1_6k.htm) filed 2026-08-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926088690/tm2621681d1_6k.htm) filed 2026-07-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926087324/tm2621474d1_6k.htm) filed 2026-07-28 - [20-F](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/bgm-20250930x20f.htm) filed 2026-07-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1779578/000110465926083125/tm2620216d1_6k.htm) filed 2026-07-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001779578), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BGM Group Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BGM, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BGM Group Ltd. - **Ticker**: BGM - **Listing**: NASDAQ - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG7307E1310 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BGM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bgm/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BGM Group (BGM) news: offering", 2026-10-31, https://aibio.space/companies/bgm/